ADC Therapeutics (ADCT) Competitors $4.10 +0.12 (+3.12%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$4.17 +0.07 (+1.61%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT vs. TWST, COGT, BHVN, HRMY, PAHC, VCEL, AVDL, GPCR, SDGR, and ABCLShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Twist Bioscience (TWST), Cogent Biosciences (COGT), Biohaven (BHVN), Harmony Biosciences (HRMY), Phibro Animal Health (PAHC), Vericel (VCEL), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Schrodinger (SDGR), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. ADC Therapeutics vs. Its Competitors Twist Bioscience Cogent Biosciences Biohaven Harmony Biosciences Phibro Animal Health Vericel Avadel Pharmaceuticals Structure Therapeutics Schrodinger AbCellera Biologics ADC Therapeutics (NYSE:ADCT) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Is ADCT or TWST more profitable? Twist Bioscience has a net margin of -23.51% compared to ADC Therapeutics' net margin of -220.00%. ADC Therapeutics' return on equity of 0.00% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets ADC Therapeutics-220.00% N/A -53.73% Twist Bioscience -23.51%-29.03%-21.77% Which has more risk & volatility, ADCT or TWST? ADC Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ADCT or TWST? 41.1% of ADC Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor ADCT or TWST? In the previous week, ADC Therapeutics had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 7 mentions for ADC Therapeutics and 4 mentions for Twist Bioscience. ADC Therapeutics' average media sentiment score of 1.04 beat Twist Bioscience's score of 0.22 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, ADCT or TWST? ADC Therapeutics has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.84M6.52-$157.85M-$1.57-2.61Twist Bioscience$312.97M5.99-$208.73M-$1.45-21.43 Do analysts prefer ADCT or TWST? ADC Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 88.84%. Twist Bioscience has a consensus target price of $48.90, suggesting a potential upside of 57.39%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe ADC Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Twist Bioscience 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.55 SummaryADC Therapeutics beats Twist Bioscience on 10 of the 16 factors compared between the two stocks. Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$461.70M$3.35B$6.11B$21.78BDividend YieldN/A2.28%5.66%3.55%P/E Ratio-2.6122.2886.8129.82Price / Sales6.52265.33538.9766.04Price / CashN/A46.3226.3018.31Price / Book-1.959.9012.674.65Net Income-$157.85M-$52.45M$3.30B$1.00B7 Day Performance2.22%5.05%3.55%1.20%1 Month Performance16.26%10.61%6.79%3.32%1 Year Performance24.74%25.03%72.30%13.11% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics2.93 of 5 stars$4.10+3.1%$7.75+88.8%+24.7%$461.70M$70.84M-2.61310News CoveragePositive NewsAnalyst RevisionTWSTTwist Bioscience3.7006 of 5 stars$27.00+0.3%$49.40+83.0%-28.3%$1.62B$312.97M-18.62990COGTCogent Biosciences2.6491 of 5 stars$14.13-0.2%$20.00+41.5%+41.9%$1.61BN/A-7.9480BHVNBiohaven3.1787 of 5 stars$14.68-2.1%$48.85+232.7%-66.7%$1.59BN/A-1.92239Positive NewsHRMYHarmony Biosciences4.6499 of 5 stars$27.64+0.5%$45.50+64.6%-21.2%$1.58B$714.73M8.92200PAHCPhibro Animal Health4.4488 of 5 stars$39.15+0.9%$28.40-27.5%+79.8%$1.57B$1.30B33.182,475Positive NewsVCELVericel3.1544 of 5 stars$31.79+5.2%$60.40+90.0%-25.2%$1.53B$237.22M264.94300Positive NewsAVDLAvadel Pharmaceuticals3.1185 of 5 stars$15.31-0.2%$20.86+36.2%+14.7%$1.49B$169.12M-510.3370Positive NewsGPCRStructure Therapeutics3.0925 of 5 stars$25.30+1.2%$68.67+171.4%-36.5%$1.44BN/A-24.10136SDGRSchrodinger3.3611 of 5 stars$20.04+3.8%$27.83+38.9%+17.6%$1.42B$207.54M-8.08790Analyst DowngradeABCLAbCellera Biologics2.8746 of 5 stars$4.87+2.7%$8.00+64.3%+136.0%$1.42B$28.83M-8.85500Gap Up Related Companies and Tools Related Companies TWST Alternatives COGT Alternatives BHVN Alternatives HRMY Alternatives PAHC Alternatives VCEL Alternatives AVDL Alternatives GPCR Alternatives SDGR Alternatives ABCL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ADCT) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
